This reflects the chronic biology of obesity rather than a failure of the individual and reinforces that long-term treatment is often needed
GLP-1 therapy is generally not recommended during breastfeeding due to theoretical concerns about infant exposure and caloric restriction during lactation
5,6,7 GLP-1 is a peptide produced by the cleavage of proglucagon, mainly synthesized in the intestinal mucosal L-cells, pancreatic islet -cells, and neurons in the nucleus of the solitary tract
GLP-1R agonists have reducing neuroinflammation and oxidative stress, neurotrophic effects, decreasing A deposition and tau hyperphosphorylation in AD models, which may be a potential drug for the treatment of AD
7 As the first approved dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, tirzepatide demonstrated weight loss exceeding 20% in its pivotal trials, establishing a new therapeutic ceiling